Discover investment opportunities in Undervalued Healthcare Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Undervalued Healthcare Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Undervalued Healthcare Stocks using our Smart AI Filter.
10 stocks found for "Undervalued Healthcare Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.60 | ±27.2% | 15.6 | 3.47% | |||
0.38 | ±27.2% | 10.2 | 1.89% | |||
0.54 | ±25.7% | 19.5 | 0.39% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.77 | ±40.2% | 10.4 | 3.94% | |||
0.35 | ±28.9% | 6.7 | 5.29% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What indicates that Pfizer (PFE) might be undervalued in the current market?
A: Pfizer's low forward P/E ratio compared to industry averages may suggest undervaluation. Additionally, a consistent dividend yield and positive R&D developments could make it attractive for growth-focused investors.
Q: How does Merck (MRK) perform during economic downturns?
A: Historically, Merck has shown resilience in economic downturns due to its diverse pharma portfolio and essential medications, which may provide stable revenue streams.
Q: Is AbbVie Inc. (ABBV) considered a strong income investment?
A: AbbVie offers a high dividend yield, supported by robust cash flows. However, careful monitoring of debt levels is essential to ensure continued dividend safety.
Q: What are Bristol-Myers Squibb’s (BMY) competitive strengths?
A: Bristol-Myers Squibb benefits from a broad pipeline of targeted oncology and immunology treatments, providing competitive advantages in high-demand health segments.
Q: Does Gilead Sciences (GILD) offer potential in emerging markets?
A: Gilead's focus on HIV and antiviral treatments offers growth potential in emerging markets, where healthcare needs and access continue to expand.
Q: What risks are associated with investing in Amgen Inc. (AMGN)?
A: Amgen faces risks related to biosimilar competition and pricing pressures, which could affect market share and profitability over time.
Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. It is the latest in a string of new U.S. investments by the pharmaceutical industry as President Donald Trump threatens to clamp down on the industry with tariffs on pharmaceuticals imported into the country.
Read more